Delfi Diagnostics Appoints Jacob Van Naarden to its Board of Directors
BALTIMORE, June 22, 2022 /PRNewswire/ -- Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection and monitoring, appointed Jacob Van Naarden, Senior Vice President of Eli Lilly and Company and CEO of Loxo@Lilly, to its board of directors.